amlodipine camsylate | 652969-01-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: amlodipine camsylate
• 英文别名: [(1S,4R)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid;3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 652969-01-2
• 化学式: C₁₀H₁₆O₄S*C₂₀H₂₅ClN₂O₅
• 分子量: 641.183
• InChiKey: UXKMFEPPKJZDAR-STOWLHSFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.54
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  180
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  氨氯地平 、 (1S)-(+)-10-camphorsulfonic acid 在 甲醇 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以to obtain 16.7 g (yield: 86.8%) of the title compound in the form of a white crystal的产率得到amlodipine camsylate
  参考文献：
  名称：

  Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof

  摘要：

  本发明涉及一种稳定的、无定形的氨氯地平卡络亚酸盐，其具有高溶解度，可有效用于治疗心血管疾病。

  公开号：

  US20060128763A1

文献信息

• MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION
  申请人：Hwang Sung Joo

  公开号：US20110200678A1

  公开（公告）日：2011-08-18

  The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.

  本发明涉及一种新型技术，用于从可溶于液体溶剂且不会被热分解的固体中形成粒径为0.02〜3微米的细小颗粒。本发明的颗粒制备技术可适用于食品、化妆品、生物聚合物、聚合物组合物和制药等领域。
• [EN] NOVEL AMLODIPINE CYCLAMATE SALT AND A PREPARATION METHOD THEREOF<br/>[FR] NOUVEAU SEL CYCLAMATE D'AMLODIPINE ET PROCEDE DE PREPARATION
  申请人：DAE WOONG PHARMA

  公开号：WO2004072036A1

  公开（公告）日：2004-08-26

  The present invention provides amlodipine cyclamate, a novel pharmaceutically acceptable acid addition salt of amlodipine, which is a potent and long-acting calcium channel blocker useful as an anti-ischemic or anti-hypertensive agent. Amlodipine cyclamate, which may be prepared by reacting amlodipine with cyclamic acid, has pharmacologically excellent properties such as low toxicity, and high stability, solubility, non-hygroscopicity, and processability.

  本发明提供了氨氯地平环糊精，一种新型药用酸盐，是一种有效的长效钙通道阻滞剂，可用作抗缺血或抗高血压药物。氨氯地平环糊精可以通过将氨氯地平与糖精酸反应制备而成，具有药理学上卓越的性能，如低毒性、高稳定性、溶解度、不吸湿性和加工性。
• [EN] STABLE AMORPHOUS AMLODIPINE CAMSYLATE, PROCESS FOR PREPARING SAME AND COMPOSITION FOR ORAL ADMINISTRATION THEREOF<br/>[FR] AMLODIPINE CAMSYLATE STABLE ET AMORPHE, PROCEDE DE PREPARATION ASSOCIE ET COMPOSITION POUR L'ADMINISTRATION ORALE
  申请人：HANMI PHARM IND CO LTD

  公开号：WO2004067512A1

  公开（公告）日：2004-08-12

  This invention relates to a stable, amorphous form of amlodipine camsylate having a high solubility which can be efficiently used in treating cardiovascular diseases.

  这项发明涉及一种稳定的无定形氨氯地平卡瑞酸盐，具有高溶解度，可有效用于治疗心血管疾病。
• Novel amlodipine camsylate and method for preparing thereof
  申请人：——

  公开号：US20040116478A1

  公开（公告）日：2004-06-17

  Amlodipine camsylate of the present invention is a crystalline salt of amlodipine suitable for pharmaceutical formulation, which is prepared by using low toxic camphor sulfonic acid to meet required pharmaceutical properties for treating cadiovacular diseases.

  本发明的氨氯地平卡姆酸盐是一种适用于制药配方的氨氯地平结晶盐，采用低毒性樟脑磺酸制备，以满足治疗心血管疾病所需的药物性质。
• COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS
  申请人：Kim Sung Wuk

  公开号：US20080241240A1

  公开（公告）日：2008-10-02

  The present invention relates to a chronotherapeutic combination pharmaceutical formulation, which is designed to control the release of each ingredient of the combined drug in a predetermined rate based on the principle of the so-called chronotherapy and xenobiotics, where drugs are administered to exhibit pharmacological activities at predetermined time intervals. The formulations of the present invention comprise a dihydropyridine, and a statin, as active ingredients. The formulations are structured and arranged such that the respective release rates of the above ingredients can be controlled, thereby reducing or preventing antagonistic effects and side effects resulting from the interaction of the above ingredients, while maintaining the synergistic effect, and providing easy medication.

  本发明涉及一种时间治疗组合药物配方，旨在根据所谓的时间治疗和异物代谢原理，设计控制联合药物中每种成分的释放速率，其中药物在预定时间间隔内给予以展现药理活性。本发明的配方包括二氢吡啶和他汀作为活性成分。该配方的结构和排列使得上述成分的释放速率可以被控制，从而减少或预防由上述成分相互作用引起的拮抗作用和副作用，同时保持协同作用，并提供方便的药物治疗。